Pediatrics Doctors in Lucedale, MS Accepting Medicare

3 Pediatrics doctors found. Showing 1 - 3

Dr. Natoya Barnett-grindley, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 92 Ratliff St, Lucedale, MS 39452 Phone: 601-947-8181    Fax: 601-947-4411

Jennifer Lashay Atkins, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 92 Ratliff St, Lucedale, MS 39452 Phone: 601-947-8181

Dr. Tara S. Mallett, D.O. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 92 W. Ratliff Street, Lucedale, MS 39452 Phone: 601-947-8181    Fax: 601-947-4411

News Archive

Cancer patients have impaired antibody responses to COVID-19 mRNA vaccines

A new study posted to the medRxiv* preprint server studies the neutralizing antibody response in cancer patients diagnosed with chronic lymphocytic leukemia (CLL), lung cancer, breast cancer, and various non-Hodgkin's lymphomas (NHL), post-reception of two doses of messenger RNA (mRNA) vaccines.

U.N. official calls report on WFP in Somalia 'misleading'; WFP discusses plans to ramp up food aid to Niger, Uganda

The U.N. top aid chief "in Somalia has fired back at a report that suggests food aid is being skimmed off by contractors as 'a cost of doing business' in the war-torn nation, an allegation he calls 'completely misleading,'" CNN reports.

ALung closes $10 million Series B financing round

ALung Technologies, Inc., a leading developer of advanced respiratory products, announced today that it has closed a $10 million Series B financing round. The investment will support the continued commercialization of ALung's flagship product, the Hemolung Respiratory Assist System (RAS), which provides partial respiratory assistance to patients in acute respiratory failure.

Miniature injectable biosensor could offer continuous, long-term alcohol monitoring

Engineers at the University of California San Diego have developed a miniature, ultra-low power injectable biosensor that could be used for continuous, long-term alcohol monitoring.

Sorafenib stops tumor growth, provides effective treatment for thyroid cancer patients

The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial, which will be presented today by a researcher from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania in a plenary session during the American Society of Clinical Oncology's annual meeting.

Read more Medical News

› Verified 2 days ago